Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
- The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP).
- ADX-2191 is a methotrexate for intravitreal injection.
- Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
- Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Orphan Drug DesignationBiotech News Health Care Small Cap FDA General
